ArticleBreast cancer research and treatment2026
Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe KEYNOTE-522 clinical trial demonstrated that the addition of pembrolizumab to 8 cycles of neoadjuvant chemotherapy (NAC) improves pathologic complete response (pCR) rates and overall survival in early-stage triple-negative breast cancer (TNBC). However, predictors of response and the benefit of alternative NAC backbones with immunotherapy are not known. This multi-institutional study evaluates clinical factors and treatment variables associated with pCR following NAC plus pembrolizumab in a diverse, real-world cohort.
methodsThis multi-institution retrospective study analyzed patients with early-stage TNBC diagnosed between July 1, 2021, and December 31, 2023, across three hospital systems. Eligible patients received at least one cycle of NAC and pembrolizumab. Predictors of pCR were assessed using logistic regression.
resultsOf the 374 patients included, the pCR rate was 61.2%. The cohort was racially and ethnically diverse, with 29.1% of patients identifying as non-White. Almost half (48.4%) had a BMI ≥30, and 70 patients (18.7%) had pre-existing diabetes mellitus. Approximately two-thirds (64.4%) completed 8 cycles of neoadjuvant pembrolizumab, while 72.5% completed 8 cycles of NAC. On univariate analysis, age less than 55 years (p = 0.03), absence of diabetes mellitus (p = 0.03), high tumor grade (p = 0.005), the completion of 8 or more cycles of neoadjuvant pembrolizumab (p = 0.04) and 8 cycles of NAC (p = 0.03) were associated with pCR. There was a trend towards higher pCR rates with the receipt of at least one cycle of anthracycline-cyclophosphamide (p = 0.07). Lack of diabetes mellitus (p = 0.03) and high tumor grade (p = 0.004) remained significant on multivariate analysis.
conclusionThis study supports the use of KEYNOTE-522 in a diverse, real-world population of patients with early-stage TNBC. Patients with diabetes were less likely to achieve a pCR, suggesting a potential impact of glucose metabolism on chemo-immunotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.